Tonix Pharmaceuticals Initiates Enrollment in the RESILIENT Study, a Potentially Pivotal Phase 3 Study of TNX-102 SL for the Management of Fibromyalgia
April 07, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Results from Planned Interim Analysis Expected First Quarter 2023 A Positive Outcome in RESILIENT Together with Results from Previous Positive Phase 3 Study RELIEF May Support Submission of an NDA ...
Tonix Pharmaceuticals Announces IND Clearance for TNX-102 SL as a Potential Treatment for Long COVID Syndrome, Also Known as Post-Acute Sequelae of COVID-19 (PASC)
April 06, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Phase 2 Clinical Trial of TNX-102 SL for the Treatment of Long COVID Expected to Start Second Quarter 2022 Long COVID Afflicts More Than 30% of Patients Following Infection with SARS-CoV-2, the...
Tonix Pharmaceuticals Announces Extension of Sponsored Research Agreement with Kansas State University to Develop Live-Virus Vaccine Against COVID-19
April 05, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
TNX-2300, a Live Virus Vaccine Based on a Bovine Parainfluenza Virus Vector, in Development to Protect Against COVID-19 Co-Expression of the CD40-Ligand Will be Tested to Direct Immune Response ...
Tonix Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
March 22, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, President and...
Tonix Pharmaceuticals Announces Phase 3 RALLY Study Results for TNX-102 SL 5.6 mg for the Management of Fibromyalgia
March 21, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
As Expected Based on Interim Analysis Results Reported in July 2021, TNX-102 SL Did Not Achieve Statistical Significance Over Placebo on the Primary Endpoint of Reduction in Daily Pain in RALLY Study ...
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
March 14, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Immunology and CNS Programs Entering the Clinic in 2022 for Organ Transplantation, Cocaine Intoxication, Fibromyalgia, PTSD, Migraine Headache and Binge Eating Disorder Covid-19 Programs...
Tonix Pharmaceuticals Announces Appointment of Jeffrey Rosenfeld, Ph.D., as Executive Director, Genomics and Bioinformatics
March 09, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the...
Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Evaluate TNX-1900 (Intranasal Potentiated Oxytocin) for Treating Binge Eating Disorder
March 07, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
An Investigator Initiated Phase 2 Clinical Trial of TNX-1900 In Patients with Binge Eating Disorder Planned for Second Half 2022 Binge Eating Disorder is Estimated to Affect 2.8 Million American...
Tonix Pharmaceuticals Announces FDA Orphan-Drug Designation for TNX-2900 for the Treatment of Prader-Willi Syndrome
March 03, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the U.S....
Tonix Pharmaceuticals Announces Research Agreement with the French National Institute of Health and Medical Research (Inserm) to Study the Mechanism of Oxytocin-Mediated Improvement of Eating Behaviors in Prader-Willi Mice
February 28, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Tonix is Developing TNX-2900 (Intranasal Potentiated Oxytocin) for the Treatment of Prader-Willi in Adolescents and Adults with Hyperphagia or Excessive Eating Planned Studies in Prader-Willi Mice...